Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models.

CONCLUSION: Prexasertib has significant anti-tumor effects as a monotherapy or in combination with chemotherapy in multiple preclinical models of pediatric cancer. These findings support further investigation of prexasertib in pediatric malignancies.
PMID: 30563935 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 18, 2018 Category: Cancer & Oncology Authors: Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Bence Lin A, P Beckmann R, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Tags: Clin Cancer Res Source Type: research